



CAPITAL INCREASE IN GENMAB AS A RESULT OF EMPLOYEE WARRANT EXERCISE

Summary: Genmab A/S increases its share capital by 13,611 shares as a result of employee warrant exercise.

Copenhagen, Denmark; November 21, 2007 – Genmab A/S (OMX: GEN) has decided to increase its share capital by 13,611 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following prices per share of nominally DKK 1: 1,000 shares at DKK 37.00, 1,200 shares at DKK 86.00, 2,850 shares at DKK 89.50, 3,687 shares at DKK 101.00, 1,125 shares at DKK 114.00, 1,000 shares at DKK 173.00 and 2,749 shares at DKK 224.00. Proceeds to the company are approx. DKK 1.7 million (approx. TUSD 335). The increase corresponds to approx. 0.03 % of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2007. The new shares will be listed on the OMX Nordic Exchange Copenhagen A/S after registration with the Danish Commerce and Companies Agency. Genmab A/S' current share capital amounts to DKK 44,506,216 and will after the capital increase be DKK 44,519,827. The capital increase is expected to be finalized shortly.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets,

CAPITAL INCREASE IN GENMAB AS A RESULT OF EMPLOYEE WARRANT EXERCISE

our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab[®]; the Y-shaped Genmab logo[®]; HuMax[®]; HuMax-CD4[®]; HuMax-CD20[®]; HuMax-EGFr[™]; HuMax-IL8[™]; HuMax-TAC[™]; HuMax-HepC[™]; HuMax-CD38[™]; and UniBody[®] are all trademarks of Genmab A/S.

Contact: Helle Husted, Sr. Director, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: hth@genmab.com

###